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Background: Few studies have investigated the experiences of patients around
the conversion to secondary progressive multiple sclerosis (SPMS). ManTra is a
mixed-method, co-production research project conducted in Italy and Germany to
develop an intervention for newly-diagnosed SPMS patients. In previous project actions,
Solari et al. Conversion to Secondary Progressive Multiple Sclerosis
we identified the needs and experiences of patients converting to SPMS via literature
review and qualitative research which involved key stakeholders.
Aims: The online patient survey aimed to assess, on a larger and independent
sample of recently-diagnosed SPMS patients: (a) the characteristics associated to patient
awareness of SPMS conversion; (b) the experience of conversion; (c) importance and
prioritization of the needs previously identified.
Methods: Participants were consenting adults with SPMS since ≤5 years. The survey
consisted of three sections: on general and clinical characteristics; on experience
of SPMS diagnosis disclosure (aware participants only); and on importance and
prioritization of 33 pre-specified needs.
Results: Of 215 participants, those aware of their SPMS diagnosis were 57% in Italy vs.
77% in Germany (p = 0.004). In both countries, over 80% of aware participants received
a SPMS diagnosis from the neurologist; satisfaction with SPMS disclosure was moderate
to high. Nevertheless, 28–35% obtained second opinions, and 48–56% reported they did
not receive any information on SPMS. Participants actively seeking further information
were 63% in Germany vs. 31% in Italy (p < 0.001).
Variables independently associated to patient awareness were geographic area (odds
ratio, OR 0.32, 95% CI 0.13–0.78 for Central Italy; OR 0.21, 95% CI 0.08–0.58 for
Southern Italy [vs. Germany]) and activity limitations (OR 7.80, 95% CI 1.47–41.37 for
dependent vs. autonomous patients).
All pre-specified needs were scored a lot or extremely important, and two prioritized
needs were shared by Italian and German patients: “physiotherapy” and “active patient
care involvement.” The other two differed across countries: “an individualized health care
plan” and “information on social rights and policies” in Italy, and “psychological support”
and “cognitive rehabilitation” in Germany.
Conclusions: Around 40% of SPMS patients were not aware of their disease form
indicating a need to improve patient-physician communication. Physiotherapy and active
patient care involvement were prioritized in both countries.
Keywords: multiple sclerosis, conversion, secondary progressive multiple sclerosis, online survey, patient needs,
patient-physician communication
INTRODUCTION
About 15 years after clinical onset, around half of the
patients with relapsing-remitting multiple sclerosis (RRMS) have
developed secondary progressive disease (SPMS). This disease
form is characterized by irreversible disability progression that
is independent of a relapse, although patients with SPMS can still
experience relapses (1, 2). Conversion from RRMS to SPMS is
considered a key determinant of long-term disease prognosis (2).
However, neither imaging criteria nor biomarkers are available
to objectively distinguish RRMS from SPMS. SPMS is diagnosed
retrospectively (3–5), and the period of diagnostic uncertainty
may last for several years (3 years on average) as reported in a
retrospective cohort study including 123 patients (6).
The RRMS–SPMS transition is also critical from the
psychosocial point of view (7). As well as new uncertainty,
people with SPMS, their families and health professionals (HPs)
involved in patient care all have to adjust to the new reality of
unremitting symptoms and activity limitations, and scarcity of
effective disease modifying treatments (DMTs) for this disease
form (8).
From a review of the literature, we found four studies on the
experiences of patients around the RRMS–SPMS transition (9–
12). All employed qualitative research and were conducted in
the United Kingdom. Davies et al. identified four main themes
envisaged by patients and carers: “realization” of the conversion
to SPMS, “reaction” to this realization, “realities” of living with
SPMS (dealing with the healthcare system during this period),
and “future challenges” (9). The same group also explored the
experiences of HPs supporting patients during the transition (10).
Two main themes were found: “transition” which comprised
issues related to recognizing and communicating about SPMS
and “providing support” which included descriptions of
challenging aspects of patient care, namely support for caregivers,
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multidisciplinary care and service limitations (10). Hourihan
identified five themes from patient experiences: naming of the
process of change, psychological consequences, consequences to
occupations, impact on relationships, and coping with a life of
change (11). Finally, O’Loughlin et al. focused on patient and HP
experiences, and suggested a process of moving from uncertainty
toward confirmation of patient’s diagnostic label, the experience
of which was moderated by HP attitudes and approaches (12).
Managing the Transition to SPMS (ManTra) is a mixed-
method project conducted in Italy and Germany that adheres
to the Medical Research Council framework for developing and
evaluating complex interventions (13). The project goals were
2-fold: to assess the experiences and the needs of people who
recently converted to SPMS, using qualitative and quantitative
research and involving key stakeholders; and to set up a user-
led resource to empower and improve the quality of life and
autonomy of newly diagnosed patients with SPMS (14).
In previous ManTra project actions (paper in preparation),
we identified the needs of patients converting to SPMS
via literature review and a qualitative study (personal semi-
structured interviews with recently diagnosed SPMS patients;
focus groupmeetings with patient significant others, neurologists
and other HPs). The present paper reports the results of an online
patient survey which was conducted in Italy and Germany to: (1)
assess the experiences of people recently diagnosed with SPMS;
(2) verify whether the 33 needs identified in the qualitative study
which involved key stakeholders are pertinent to a larger sample
of people with SPMS. An additional aim (3) originated from the
qualitative study, and consisted in exploring the characteristics
associated to patient awareness of his/her conversion.
MATERIALS AND METHODS
Participants
The ManTra project was approved by the ethics committees
of the Fondazione IRCCS Istituto Neurologico Carlo Besta
(clearance number: 27), the G D’Annunzio University of Chieti-
Pescara (clearance number: 19), the Aldo Moro University of
Bari (clearance number: 98793CE) in Italy, and of the Hamburg
Chamber of Physicians (clearance number: PV5733) in Germany.
Patient inclusion criteria were the following: age ≥18 years;
diagnosis of SPMS 3 months to 5 years before inclusion; fluent
in Italian/German; informed consent provided (online or written
depending on participation mode, see below). Patients unable
to communicate effectively and patients with severe cognitive
compromise (referring neurologist’s judgment) were excluded.
To increase the external validity of the study, eligible patients who
could not complete the online survey were offered a telephone
interview (Italy) or paper administration (Germany).
We planned to close the survey after 2 months or after 250
patients had contributed, and to extend enrolment by another 4
months to obtain a minimum number of 180 survey participants.
To increase the external validity of the study, in Italy the MS
centers (around 250) were invited to participate via the MS
Study Group of the Italian Neurological Society. In Germany the
survey was advertised during medical consultations in the MS
day hospital of the Institute of Neuroimmunology and Multiple
Sclerosis (INIMS) in Hamburg and the Marianne Strauss Klinik
in Berg (Southern Bavaria), as well as via personal invitation
letters (two rounds) to eligible patients followed at the MS day
hospital of the INIMS.
Survey Structure and Contents
The online survey consisted of an introduction and consent page,
and of three questionnaires, presented in the following order:
questionnaire 1—on general and clinical patient characteristics;
questionnaire 2 (adapted from the Comunicazione medico-
paziente nella Sclerosi Multipla, COSM) (15, 16)—on the
experience of the SPMS diagnosis disclosure; questionnaire 3—
on the importance and prioritization of 33 pre-specified needs
identified in the ManTra qualitative study (14), and with an open
section for additional needs; an open section for comments on
the survey (Supplementary File 1). The surveys were identical in
Italy and Germany, except for the patient determined disability
scale (PDDS) (17), which was embedded in questionnaire 1 in
Germany only. The survey was devised in Italian, and then
translated into German.
From the ManTra qualitative study it emerged that only 40%
of the patients who had converted to SPMS in the preceding
5 years were aware of their conversion, thus we changed the
original (static) structure of the online survey into an adaptive
one. This change and the new sample size estimation were
major amendments to the study protocol (14). Specifically, two
filter questions were added at the end of questionnaire 1: “Have
you heard about SPMS before participating in this survey?”
and “Do you have SPMS?” Patients answering “no” to the first
filter question were not presented the second filter question
and questionnaire 2. Patients answering “no”/”don’t know” to
filter question 2 were not presented questionnaire 2. Finally, the
introduction of questionnaire 3 differed based on response to the
filter questions (Supplementary File 1).
Before fielding the survey, its usability and functionality was
tested on five Italian patients with SPMS. The online survey
fulfilled the Checklist for Reporting Results of Internet E-Surveys
(CHERRIES) criteria (18).
Procedure
The MS neurologist identified potentially eligible SPMS patients
and invited them to participate in the survey by contacting
via email or telephone the ManTra coordinating unit (Italy)
or the INIMS (Germany). Eligible patients were given the
credentials to access the dedicated website (Survey Monkey
in Italy; Unipark in Germany). Both platforms were password
protected to ensure patient data protection and also to prevent
patients from completing the questionnaires more than once.
No incentives (monetary or non-monetary) were offered to
survey participants. In addition, the MS neurologist provided
the ManTra coordinating unit the following information for each
survey participant: ExpandedDisability Status Scale (EDSS) score
(19), age at MS diagnosis, age at SPMS diagnosis.
Data Analysis
The original sample size estimation based on the COSM-S section
2 score (14) was revised, based on the results of the ManTra
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qualitative study. We estimated (one-sample comparison) that
171 patients are sufficient to detect, with a power of 0.80, a
proportion of 0.40 patients not aware of their SPMS diagnosis,
compared to a hypothesized value of 0.30, at a two-sided alpha
level of 0.05.
Variables were summarized using both counts and
percentages, mean with standard deviation (SD), or median with
minimum and maximum. Categorical variables were compared
using the chi-square or the Fisher’s exact test, and continuous
variables using unpaired t-test or Wilcoxon rank-sum test
(between-group comparisons), and paired t-test or Wilcoxon
matched-pairs signed-ranks test (within-group comparisons)
as appropriate. The normality assumption was tested using the
Shapiro–Wilk’s test.
Agreement of patient- and neurologist-reported age at MS
diagnosis and age at SPMS diagnosis was assessed with the intra-
class correlation coefficient (ICC) for continuous data (20), and
95% confidence intervals (CI). Absolute-agreement ICCs were
calculated usingmixed effects models. Bland-Altman (difference)
plot were also applied to look for any systematic bias, and to
identify possible outliers (21).
The contributions of potentially explanatory variables
to patient’s awareness of conversion to SPMS was assessed
using logistic regression, calculating crude and adjusted
odds ratios (ORs), and 95% CI. The independent variables
were: patient age (years); gender; education (two categories:
primary or secondary; university degree or higher); geographic
area (four categories: Germany, North/Center/South Italy);
time from SPMS conversion (years; physician-determined);
EDSS (physician-determined); and activity limitations
(three categories: fully autonomous, partially dependent,
fully dependent). Goodness of fit of the logistic model was
assessed using the Hosmer-Lemeshow test. Sensitivity analysis
was performed after exclusion of SPMS patients who transitioned
from more than 5 years in Italy (protocol deviations) (14).
All analyses were performedwith the Stata Statistical Software,
release 12.0 (Stata Corp LP, College Station, USA).
RESULTS
Between July and December 2018, 215 patients participated in
the survey, 141 in Italy and 74 in Germany. Survey acceptability
was satisfactory in Italy, with few participants abandoning the
survey after reading the information (23/164, 14%); in Germany
figures were higher, with 85/159 (53%) of the invited patients not
participating in the survey. Missing data were few: 14 patients
did not report age at SPMS diagnosis, four patients skipped the
item on activity limitations, one patient the item on work status,
and one patient the item on living conditions. Data quality check
(logical and coherence of patient-provided information and of
patient and neurologist-provided information) was satisfactory.
Overall, 39% of the participants provided comments (64/141 in
Italy, 19/74 in Germany) which were positive in 92%.
The 25 Italian centers were from the three geographical areas
(Table 1); 11 (44%) were hospitals, 9 (36%) university hospitals,
three (12%) research hospitals, and two (8%) outpatient centers.
Mean patient age was 52.7 years (SD 8.7), 143 (67%) were women,
and 55 (26%) had university degree or higher. Median EDSS
score was 6.0 (range 2.0–9.0). Mean age at MS diagnosis was 35.2
years (SD 10.5), and mean age at SPMS diagnosis 49.8 years (SD
8.9). Table 1 show participant characteristics by country and by
awareness of conversion to SPMS.
Overall, 138 participants (64%) were aware of their conversion
to SPMS. Figures differed across the countries, with 57% of
aware patients in Italy vs. 77% in Germany (p = 0.004). One
Italian patient aware of his conversion did not remember when
it occurred; corresponding figures in Germany were 14/57 (25%).
Twenty one participants (12 in Italy, 9 in Germany) had SPMS
since more than five years.
Experience of Conversion to SPMS
Table 2 reports findings on the adapted COSM questionnaire
in the two countries. The neurologist was the person who
communicated the SPMS diagnosis to more than 80% of
patients. Satisfaction with SPMS disclosure was moderate to
high in both countries. Nevertheless, some 28–35% participants
obtained one or more second opinions, and 48–56% reported
that they did not receive any information on their disease
form. Those who received information were moderately to a
lot satisfied for information completeness, while satisfaction
for information understandability was higher in Germany
(p = 0.05). The proportion of those who actively sought
further information about SPMS was also higher in Germany
(63%) than Italy (31%; p < 0.001), the web being the main
information source in both countries. Besides neurologists,
the most reported HPs who followed the patients after SPMS
diagnosis were physiotherapists in both countries, followed by
rehabilitation physicians, psychologists and urologists in Italy,
and by occupational therapists and psychologists in Germany.
Reliability of Age at Conversion to SPMS
Agreement between patients and neurologists was excellent
for age at MS diagnosis (200 observations; ICC 0.91; 95%
CI 0.88−0.93; p < 0.001), while it was moderate for age
at SPMS transition (123 observations; ICC 0.69; 95% CI
0.54−0.79; p< 0.001).
The Bland-Altman plot revealed that patients systematically
reported an earlier age at SPMS conversion than neurologists
(on average 2.7 years earlier; Figure 1, lower graph). Six per
cent of the differences were out of the limits of agreement for
both age at MS diagnosis (12/200) and age at SPMS transition
(7/123). In no instance the differences seemed to be affected by
the magnitude of the average age (at MS diagnosis, and at SPMS
transition, respectively).
Predictors of Patient Awareness of SPMS
Conversion
In univariate analysis, the only variable associated to patient
awareness of SPMS conversion was the geographic area.
There was a north-south gradient (from 77 to 64%, 54%,
47%) and the OR was 0.35 (95% CI 0.15–0.78) for patients
from Central Italy and 0.26 (95% CI 0.11–0.64) for patients
from Southern Italy vs. Germany (reference category; Table 3).
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TABLE 1 | Characteristics of participants to the online survey by country and by awareness of conversion to secondary progressive multiple sclerosis (SPMS).
Italy (n = 141) Germany (n = 74)
Characteristic Aware (n = 81) Not aware/unsure (n = 60) P-value Aware (n = 57) Not aware/unsurec (n = 17) P-value
N (%) N (%)
Age, yearsa 52.3 (0.9) 37–72 50.8 (1.1) 34–72 0.29 54.5 (8.7) 36–80 54.8 (11.7) 42–84 0.57
Women 38 (63) 53 (65) 0.86 38 (67) 14 (82) 0.21
Education (years)
Primary school (8) 15 (19) 17 (28) 9 (16) 0
Secondary school (13) 40 (49) 27 (45) 30 (53) 14 (82)
University degree or higher (16+) 26 (32) 16 (27) 0.79 18 (32) 3 (18) 0.08
Work
Retired (disability) 27 (33) 17 (28) 15 (27) 3 (18)
Full time 20 (25) 14 (23) 2 (4) 3 (18)
Part-time 14 (17) 7 (12) 11 (20) 2 (12)
Housewife 12 (15) 6 (10) 2 (4) 1 (6)
Unemployed 3 (4) 9 (15) 2 (4) 0
Retired (age) 3 (4) 2 (3) 22 (39) 7 (41)
Other 2 (2) 5 (8) 0.04 2 (4) 1 (6) 0.43
Status
Married/cohabiting 56 (69) 43 (72) 41 (73) 9 (60)
Single 12 (15) 10 (17) 7 (12) 4 (24)
Widow/widower 8 (10) 4 (7) 7 (12) 4 (24)
Separated/divorced 5 (6) 3 (5) 0.89 1 (2) 0 0.36
Country area (centers in Italy)
North (12) 45 (56) 25 (42) 55 (96) 15 (88)
Center (8) 22 (27) 19 (32) 0 0
South (5) 14 (17) 16 (27) 0.22 2 (4) 2 (12) 0.22
Age at MS diagnosisa
Patient reported 35.4 (10.4) 17–62 33.7 (10.3) 14–61 0.92 34.0 (13.3) 14–69 33.2 (13.6) 19–72 0.60
Neurologist reported 36.5 (10.2) 20–61 34.0 (9.4) 15–64 0.14 35.3 (11.3) 19–70 31.5 (12.7) 19–72 0.29
Age at SPMS diagnosisa
Patient reported 45.7 (8.7) 25–66 n.a. 50.7 (8.1) 37–75 n.a.
Neurologist reported 48.8 (8.0) 33–65 47.9 (8.6) 30–72 0.51 52.4 (9.1) 32–77 53.1 (11.4) 38–79 0.81
EDSSb 6.0, 1.0–8.5 6.0, 3.0–7.0 0.25 6.0, 2.0–9.0 6.0, 3.0–8.5 0.31
Patient reported activity limitations
Fully autonomous 18 (22) 21 (35) 14 (26) 3 (19)
Partially dependent 54 (67) 38 (63) 35 (65) 11 (69)
Fully dependent 9 (11) 1 (2) 0.04 5 (9) 2 (12) 0.83
PDDSb 6.0, 5.0–8.0 5.0, 5.0–8.0 0.46
Mode of participation
Online (web survey) 63 (78) 40 (67) 32 (56) 12 (71)
Telephone interview 18 (22) 20 (33) n.a. n.a.
Paper n.a. n.a. 0.14 25 (44) 5 (29) 0.22
EDSS, expanded disability status scale; PDDS, patient determined disability scale; n.a., not applicable.
aMean (SD) minimum—maximum.
bMedian, minimum—maximum.
c In the German sample there were the following missing data: 14 for age at SPMS diagnosis (patients who did not remember it), 4 for activity limitations, 1 for work and status.
The multivariate model confirmed the independent effect of
geographic area: OR 0.38 (95% CI 0.16–0.90) for Central Italy,
OR 0.25 (95% CI 0.10–0.63) for Southern Italy (vs. Germany).
In addition, patient self-determined activity limitations had
an independent effect, with patients fully dependent having
a higher odds of being aware of their SPMS conversion
compared to those fully autonomous (reference category; OR
6.20, 95% CI 1.22–31.43; Table 3). The goodness of fit of
the logistic model was satisfactory, and the sensitivity analysis
performed after exclusion of 21 patients who transitioned
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TABLE 2 | Patient self-assessed experience of the secondary progressive multiple sclerosis (SPMS) diagnosis disclosure (section 1, five items) and following period.
Characteristic Italy (n = 81) Germany (n = 57) P-value
N (%)
Conversion to SPMS disclosed by:
Neurologist 66 (81) 47 (82)
Personal medical report 10 (12) 2 (4)
Other specialist 2 (2) 6 (11)
Othera 3 (4) 2 (4) 0.08
Information on SPMS received fromb:
Neurologist 37 (46) 20 (35)
National MS Society 7 (9) 0
Other specialist 4 (5) 9 (16)
Another person with MS 3 (4) 0
General practitioner 2 (2) 3 (5)
Otherc 4 (5) 0
Not received 39 (48) 32 (56) 0.35
Information understandable:
Not at all 0 0
A little 5 (12) 2 (8)
Moderately 20 (48) 6 (25)
A lot 15 (36) 13 (54)
Extremely 2 (5) 3 (13) 0.05
Information complete:
Not at all 2 (5) 0
A little 9 (21) 3 (13)
Moderately 16 (38) 10 (42)
A lot 12 (29) 9 (38)
Extremely 3 (7) 2 (8) 0.24
Searched information from other sourcesb:
Internet 21 (26) 32 (56)
Magazines/journals 4 (5) 4 (7)
Otherd 2 (2) 1 (2)
No 56 (69) 21 (37) <0.001
Satisfied with disclosure (replied 67/81, 83% in Italy; 49/57, 86% in germany):
Not at all 1 (2) 0
A little 11 (16) 7 (14)
Moderately 27 (40) 18 (37)
A lot 20 (30) 19 (39)
Extremely 8 (12) 5 (10) 0.52
Consultation for second opinion (80/81 replies in Italy, 99%):
Yes 22 (28) 20 (35)
No 58 (72) 37 (65) 0.34
Followed by other HPs (80/81 replies in Italy, 99%)b: At center Out of center At center Out of center
Physiotherapist 8 (10) 12 (15) 1 (2) 10 (18)
Physiatrist 8 (10) 5 (6) 1 (2) 2 (4)
Psychologist 7 (9) 3 (4) 1 (2) 3 (5)
Urologist 5 (6) 5 (6) 1 (2) 5 (9)
Occupational therapist 2 (2) 0 1 (2) 7 (12)
Othere 2 (2) 7 (9) 1 (2) 1 (14)
No 57 (71) 40 (70) 0.98
Adapted from the Comunicazione medico-paziente nella Sclerosi Multipla, (COSM) questionnaire (15, 16) HP, health professional.
aNurse (one in Italy, two in Germany), publication of the Italian MS Society, other publication.
bTotals exceed 81/57 as more than one option can be selected.
cRelative (n = 2), friend, nurse.
dTV, another person with MS (one in Italy, one in Germany).
eFromMS center: Speech therapist (n= 1 Germany) neuropsychologist (n= 1 Italy), sexologist (n= 1 Italy). Out of center: Speech therapist (n= 1 Italy, n= 1 Germany), gastroenterologist
(n = 1 Italy), gynecologist (n = 1 Italy), ophthalmologist (n = 1 Italy), orthopedic (n = 1 Italy), proctologist (n = 1 Italy), vascular surgeon (n = 1 Italy).
Bold values are those statistically significant.
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FIGURE 1 | Bland-Altman plots for age at MS diagnosis (upper graph; n =
200) and age at SPMS diagnosis (lower graph; n = 81). The middle bold line is
the average difference between the patient and neurologist reports. Two
additional lines are the upper and lower bounds of the limits of agreement (21).
from more than five years produced consistent findings
(Supplementary Table 1).
Needs Importance and Prioritization
Patients scored all the 33 pre-specified needs as a lot to extremely
important, without any differences between those aware and not
aware/unsure of their conversion to SPMS, and across countries
(Supplementary Table 2).
The top four prioritized needs in Italy were “physiotherapy
and exercise programs” (prioritized by 43% of survey
participants), followed by “personalized care plan” (33%),
“patient active involvement in care” (21%), and “information
on social rights and policies” (17%), with a lower proportion of
prioritization of the last need for patients who were aware of their
SPMS conversion (Supplementary Table 2). Top prioritized
needs in Germany were “physiotherapy and exercise programs”
(prioritized by 40% of survey participants), followed by “patient
active involvement in care” (22%), “psychological support for
patients” (22%), and “cognitive rehabilitation” (21%), with
similar percentages between aware and not aware patients.
DISCUSSION
To our knowledge, this is the first survey assessing the experience
of people recently diagnosed with SPMS. The qualitative
study that preceded the survey was key to revise the survey
structure, which was adapted to the participant awareness.
Patient participation was high in Italy.
Notably, the revised structure allowed to assess the proportion
of patients who were aware of their SPMS conversion. This
proportion was overall low, and in part explained by the difficulty
in defining this disease form (1, 6, 22). Consistently, whilst
the patient-neurologist agreement on age at MS diagnosis was
excellent, this was not the case for age at SPMS conversion.
Patients reported an age at SPMS conversion 2.7 years lower
on average than neurologists, suggesting that they identified
disease progression before SPMS was medically confirmed
(Figure 1). Interestingly in the study by Katz-Sand et al. the
period of diagnostic uncertainty was 2.9 years, very close to
the difference between patient and physician classifications in
our survey (6). Nevertheless, the difference between patient-
and neurologist reported age at SPMS conversion might be due
to a purposeful late communication by the neurologist (e.g.,
to prevent patient frightening, or DMT discontinuation). In
Germany the proportion of aware patients was higher than in
Italy (77 vs. 57%), however 25% of the German patients who
were aware did not remember at which age they transitioned
to SPMS.
Formulation of a SPMS diagnosis is not straightforward,
nevertheless it is a key prognostic factor that may affect decisions
and planning at the health care level (e.g., DMT change or
discontinuation, provision of psychosocial support, shift to a
multidisciplinary care) (23–25) and at the personal level. For
these reasons, a clear and effective communication to the patient
is an ethical imperative. Sharing with the patient also the period
of diagnostic uncertainty, which can take some years (16), can
prepare the patient to receive a confirmed SPMS diagnosis,
preventing unexpected and inapt disclosure. Then inherent
difficulty in diagnosing transition is combined with the difficult
meaning for patients and physicians further challenging the
communication. Davies et al. point out that not only patients
but also HPs may need support to enter into the “possible
SPMS” communication (10). Finally, delayed SPMS diagnosis
disclosure may hinder treatment research on patients in the
transition phase.
The logistic model found that patients fully dependent in
activities of daily living were at higher odds of being aware of
their conversion to SPMS, indicating that they probably realized
that they had achieved irreversible disability progression. It is
also worth mentioning the lower awareness of patients living in
southern geographic area of Italy, pointing to a need to improve
communication particularly in these contexts. While the shared
decision-making competencies of MS neurologists were similar
in Germany and Italy (26, 27), the decision-making preferences
of MS patients seem to differ between these two countries,
with German patients preferring a more active role (28, 29).
This difference is paralleled in the higher proportion of patients
who actively searched for further information about SPMS in
Germany. It is possible that both cultural factors and differences
in health system organization contributed to the differences in
patient awareness of their SPMS conversion across geographic
areas of the present survey.
Frontiers in Neurology | www.frontiersin.org 7 August 2019 | Volume 10 | Article 916
Solari et al. Conversion to Secondary Progressive Multiple Sclerosis
TABLE 3 | Variables associated with patient awareness of conversion to secondary progressive multiple sclerosis (SPMS).
Characteristic At risk n Events n (%) Crude OR (95% CI) P-value Adjusted OR (95% CI)a P-value
Age, years 215 n.a. 1.02 (0.99–1.05) 0.22 1.00 (0.97–1.05) 0.77
Sex
Men 72 47 (65) 1 1
Women 143 91 (64) 0.93 (0.51–1.68) 0.81 0.88 (0.46–1.66) 0.68
Education
Primary or secondary 160 99 (62) 1 1
University degree or higher 55 39 (71) 1.50 (0.77–2.92) 0.23 1.67 (0.84–3.29) 0.15
Geographic area
Germany (2 centers) 74 57 (77) 1 1
Italy, North (12 centers) 70 45 (64) 0.54 (0.26–1.11) 0.09 0.61 (0.28–1.34) 0.22
Italy, Center (8 centers) 41 22 (54) 0.35 (0.15–0.78) 0.01 0.32 (0.13–0.78) 0.01
Italy, South (5 centers) 30 14 (47) 0.26 (0.11–0.64) 0.03 0.21 (0.08–0.58) 0.003
Time from SPMS diagnosis, years 215 n.a. 1.03 (0.94–1.12) 0.56 1.10 (0.98–1.23) 0.10
EDSS 215 n.a. 0.99 (0.80–1.23) 0.92 0.84 (0.62–1.13) 0.25
Patient reported activity limitations
Fully autonomous 56 32 (57) 1 1
Partially dependent 138 89 (65) 1.36 (0.72–2.57) 0.96 2.00 (0.88–4.53) 0.10
Fully dependent 17 14 (82) 3.50 (0.90–13.56) 0.07 7.80 (1.47–41.37) 0.02
CI, confidence interval; EDSS, expanded disability status scale; OR, odds ratio; n.a., not applicable.
aMultivariate model including all explanatory variables. Hosmer and Lemershow goodness-of-fit test: number of groups 10, χ2 5.47, p = 0.71.
Bold values are those statistically significant.
Two of the top four prioritized needs were shared by Italian
and German patients: “physiotherapy and exercise programs”
and “patient active involvement in health care.” The other two
differed across countries: in Italy they were “an individualized
health care plan” and “information on social rights and policies,”
while in Germany “psychological support for patients,” and
“cognitive rehabilitation” (Supplementary Table 2). As from
the MS Barometer (http://www.emsp.org/wp-content/uploads/
2015/08/MS-in-EU-access.pdf), access to rehabilitation varies
widely across Europe: from 100% in Belgium, Czech Republic,
Denmark, Germany, Nederland, Norway and Slovakia to ≤15%
in Cyprus, Greece, Hungary, Ireland, Romania and Spain. In
Germany physiotherapy is a long-term treatment for all patients
with SPMS; in Italy access to outpatient physiotherapy in the
public sector is limited to 40 sessions per year, and SPMS patients
have to pay for additional sessions. In most European countries
MS expertise is present mainly in tertiary rehabilitative centers,
theoretical approaches and quality standards vary widely, as the
active involvement of the patient. To improve themanagement of
patients transitioning to SPMS it is key to enhance the evidence
base on SPMS rehabilitation, chiefly integrated, multidisciplinary
approaches (30). Collaborative initiatives are needed, in the
form of pragmatic trials and comparative effectiveness research.
Equally important is an improvement in the communication
and shared decision making competences of neurologists and
other MS HPs. In the qualitative research by O’Loughlin et al.,
the cognitive, emotional and behavioral response during the
transition from RRMS to SPMS emerged as a key theme,
and information provision, a sensible communication and
psychological support were considered very important in this
disease phase (12).
The study has some limitations. The external validity of the
findings is limited by the fact that in Germany 50% of the invited
patients did not participate. It is possible that more active patients
took part, which could have inflated the proportion of those
aware of their transition to SPMS in this country. In addition,
almost all of the German participants were from themetropolitan
area of Hamburg, which is not representative of Germany as
a whole. Finally, we did not validate linguistically the German
version of the survey.
In conclusion, the study found that over 40% of recently
diagnosed SPMS patients were not aware of their disease
form, pointing to the need of an improved patient-physician
communication and information exchange, also during the
period of diagnostic uncertainty. Notably, patients who were
aware of their diagnosis were moderately to highly satisfied
with the SPMS diagnosis disclosure. Activity limitations and
geographic areas were variables independently associated to
patient awareness. Finally, all the 33 needs identified using a
qualitative approach were judged as a lot to extremely important,
and two of the four prioritized needs (physiotherapy, and
active patient care involvement) were shared by Italian and
German patients.
The next (on going) actions of the ManTra project
(developmental phase) are the outline of four resources in each
country (one for each prioritized need), guided stakeholder
consensus on the most important resource, which will be
also refined based on stakeholder input. This will lead in
each country to a user-led resource for empowering and
improving the quality of life of newly diagnosed people with
SPMS, to be tested for efficacy in the next phase of the
project (14).
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